WASHINGTON — The Trump administration is opening up the door to importing prescription drugs — at least in a limited number of cases.

The administration said Thursday that the Department of Health and Human Services will form a working group to look at the idea of importing drugs from other countries in cases in which there is a dramatic price increase for a drug produced by one manufacturer and not protected by patents or exclusivities.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

  • No one really expects this Industry Insider to improve anything. Azar merely co opted the idea. Importing drugs as long as there are specific conditions, only complicates an already cumbersome system. This is the kind of meaningless “Reforms” we can expect. The “Robust safety requirements” of the US, has been used as an excuse to deprive people of their life savings, or their very lives. This is simply catering to the corruption of the Pharma industry, which Azar chose to carefully avoid.
    They continue to tout the corrupted Free Market System which holds corporate profits over the lives of Americans. This is just a stop gap measure that will be touted as if it is meaningful, even here. This does nothing to curb the rampant price gouging, theft of public research, and criminal behavior. The failure to regulate the marketing of prescription drugs, and the refusal to enforce our laws has led to thousands of premature deaths. The fix is in, there will be no meaningful improvement here, merely this kind of nonsense. This is what happens when politicians and policy makers are bought and paid for.
    Many of these pharmaceuticals are made in dirty factories overseas, and then imported anyway.

  • Buprenorphine has been available for pain nearly 20 years, with no deaths used alone & without CNS depression, and works well. Yet ins co’s and most Medicaids refuse it for pain. That is in the middle of an opiate epidemic. Should this be about cost or saving lives?